Fatty Liver

"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Descriptor ID	D005234
MeSH Number(s)	C06.552.241
Concept/Terms	Fatty Liver Fatty Liver Liver, Fatty Steatohepatitis Steatohepatitis Steatohepatitides Steatosis of Liver Visceral Steatosis Steatoses, Visceral Steatosis, Visceral Visceral Steatoses Liver Steatosis Liver Steatoses Steatoses, Liver Steatosis, Liver

Below are MeSH descriptors whose meaning is more general than "Fatty Liver".

Diseases [C]
Digestive System Diseases [C06]
Liver Diseases [C06.552]
Fatty Liver [C06.552.241]

Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.

Bar chart showing 80 publications over 23 distinct years, with a maximum of 7 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2002	1	0	1
2004	2	0	2
2005	1	3	4
2008	2	2	4
2009	4	0	4
2010	0	2	2
2011	5	1	6
2012	1	2	3
2013	3	3	6
2014	2	0	2
2015	3	1	4
2016	4	3	7
2017	3	2	5
2018	2	0	2
2019	1	1	2
2020	2	0	2
2021	2	1	3
2022	2	1	3
2023	2	0	2
2024	1	4	5
2025	3	1	4
2026	5	1	6

Below are the most recent publications written about "Fatty Liver" by people in Profiles.

Abdolahipour R, Khuder SS, Philbrick WM, Portuphy AO, Belew GD, Fallouh HG, Muturi HT, Kim B, Kim JK, Najjar SM. Protecting CEACAM1 Expression Prevents Diet-Induced Metabolic Dysfunction and Hepatic Fibrosis in Male Mice. Obesity (Silver Spring). 2026 Nov; 34(11):2094-2108.

View in: PubMed
Ben Saad A, Arghiani N, Weilheimer AD, Gentile SD, Toles BJ, Tripathi S, Mohsin Sayed S, Chandraker A, Mullen AC. Prime editing models the MTARC1 A165T variant in human liver organoids, demonstrating reduced steatosis, inflammation, and fibrosis. Hepatol Commun. 2026 Oct 01; 10(10).

View in: PubMed
Brothwell MJ, Cao G, Maschek JA, Poss AM, Peterlin AD, Wang L, Baker TB, Shahtout JL, Siripoksup P, Pearce QJ, Johnson JM, Finger FM, Prola A, Pellizzari SA, Hale GL, Manuel AM, Watanabe S, Miranda ER, Affolter KE, Tippetts TS, Nikolova LS, Choi RH, Decker ST, Patil M, Catrow JL, Holland WL, Nowinski SM, Lark DS, Fisher-Wellman KH, Mimche PN, Evason K, Cox JE, Summers SA, Gerhart-Hines Z, Funai K. Cardiolipin deficiency disrupts electron transport chain and drives steatohepatitis. Elife. 2026 Sep 02; 14.

View in: PubMed
Gallage S, Castro RE, Estall J, Tabas I, Anstee QM, Tiniakos DG, Szabo G, Yu J, Desdouets C, Tacke F, Oakley F, Heikenwalder M. EASL position paper on preclinical models of steatotic liver disease. J Hepatol. 2026 Aug; 85(2):345-382.

View in: PubMed
Jerrett AE, Hathiramani NR, Spinelli JB. Glyceroneogenesis has a new PEP in its step(s). Cell. 2026 May 14; 189(10):2788-2790.

View in: PubMed
Szabo G, Babuta M, Ribeiro M. CLINICAL IMPLICATIONS OF INFLAMMATION IN STEATOTIC LIVER DISEASE: HETEROGENEITY OF NEUTROPHILS IN TISSUE INJURY AND HOST DEFENSE. Trans Am Clin Climatol Assoc. 2026; 136:274-286.

View in: PubMed
Matsuoka Y, Katsumata Y, Chu PS, Morikawa R, Nakamoto N, Iguchi K, Takahashi K, Kou T, Ito R, Taura K, Yazumi S, Terajima H, Honjo G, Ichihara G, Muramoto Y, Sato K, Maeda R, Hata K, Toriu N, Yanagita M, Tajima M, Fagarasan S, Yamada KI, Sugiura Y. Monitoring ferroptosis in vivo: Iron-driven volatile oxidized lipids as breath biomarkers. Redox Biol. 2025 10; 86:103858.

View in: PubMed
Colletta A, Cooper KM, Placentino G, Devuni D, Colletta C. Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes. Front Endocrinol (Lausanne). 2025; 16:1531295.

View in: PubMed
Volkert I, Grube J, Woitok MM, Mohamed MR, Edlund K, Duda JC, Dietrich J, Schneider U, Yin G, Lin C, Erschfeld S, Berger H, Candels L, Davis RJ, Bartneck M, Kühnel MP, Guillot A, Schneider KM, Schneider CV, Jonigk D, Rahnenführer J, Tacke F, Hengstler J, Trautwein C. Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency. Hepatology. 2026 Feb 01; 83(2):344-361.

View in: PubMed
Chung GE, Yu SJ, Yoo JJ, Cho Y, Lee KN, Shin DW, Kim YJ, Yoon JH, Han K, Cho EJ. Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults. Sci Rep. 2025 02 17; 15(1):5777.

View in: PubMed

People

Explore

Similar Concepts

Top Journals